0001193125-22-309544.txt : 20221221 0001193125-22-309544.hdr.sgml : 20221221 20221221070056 ACCESSION NUMBER: 0001193125-22-309544 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221220 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221221 DATE AS OF CHANGE: 20221221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACORDA THERAPEUTICS INC CENTRAL INDEX KEY: 0001008848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31938 FILM NUMBER: 221476478 BUSINESS ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 BUSINESS PHONE: 914-347-4300 MAIL ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 8-K 1 d368917d8k.htm 8-K 8-K
ACORDA THERAPEUTICS INC false 0001008848 0001008848 2022-12-20 2022-12-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 20, 2022

 

 

Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-31938   13-3831168

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2 Blue Hill Plaza, 3rd Floor,

Pearl River, NY

   10965
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (914) 347-4300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   ACOR   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

As previously disclosed, on June 22, 2022, Acorda Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days to regain compliance with the Minimum Bid Requirement.

The Company did not regain compliance with the Minimum Bid Requirement by the December 19, 2022 conclusion of the 180-day compliance period. Accordingly, on December 20, 2022, the Company received a written notice from the Staff (the “Staff Determination”) that that the Company’s common stock would be delisted from the Nasdaq Global Select Market and suspended at the opening of business on December 29, 2022, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”).

The Company intends to request a hearing before the Panel (the “Hearing”) to appeal the Staff Determination. This Hearing request will automatically stay Nasdaq’s delisting of the Company’s common stock pending the Panel’s decision. The Company expects that Nasdaq will hold the Hearing with the Panel within 45 days of the Company’s request for the Hearing, pursuant to the Nasdaq Listing Rules. At or prior to the Hearing, the Company intends to present its plans to Nasdaq to regain compliance with the Minimum Bid Requirement and request an extension of time so that the Company can regain compliance with the Minimum Bid Requirement.

The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement, including through effecting a reverse stock split. At the Special Meeting of Stockholders that concluded on November 11, 2022, the Company’s stockholders approved a proposal to authorize the Company’s board of directors to approve an amendment and restatement of the Company’s certificate of incorporation to effect a reverse stock split of the Company’s common stock by a ratio of any whole number in the range of 1-for-2 to 1-for-20, and a corresponding reduction in the number of authorized shares of the Company’s common stock, within one year following the conclusion of the special meeting. Notwithstanding the foregoing, there can be no assurance that the Panel will grant the Company an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Global Select Market.

On December 20, 2022, the Company issued a press release regarding the Staff Determination and the Company’s plan to request a Hearing. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated by reference into this Item 3.01.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    Press Release dated December 20, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Acorda Therapeutics, Inc.
December 21, 2022     By:  

/s/ Michael Gesser

    Name:   Michael Gesser
    Title:   Chief Financial Officer and Treasurer
 EX-99.1 2 d368917dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

CONTACT:

Tierney Saccavino

(917) 783-0251

tsaccavino@acorda.com

FOR IMMEDIATE RELEASE

 

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing

PEARL RIVER, NY – December 20, 2022 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company’s common stock not having regained compliance with the minimum price of $1.00, the stock is subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to submit such request within the required seven calendar days, which will stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Hearings Panel following the hearing. The Hearings Panel has the discretion to grant the Company an extension through June 17, 2023.

At the hearing, the Company intends to present a plan to achieve compliance with the Nasdaq listing requirements and to request additional time to regain such compliance. In the event that the Company receives an extension but cannot regain compliance within the extended time, the Company would effect a reverse stock split under authorization from stockholders received in November 2022. There can be no assurance that the Panel will grant the Company an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Global Select Market.

“We believe it is in the best interests of shareholders to allow the stock price to grow organically rather than effecting a reverse stock split, and will discuss this and our long-term plan with the Hearings Panel,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statements

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related restrictions on in-person interactions and travel, and the potential for illness, quarantines

and vaccine mandates affecting our management, employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to attract and retain key management and other personnel, or maintain access to expert advisors; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock; risks related to the successful implementation of our business plan, including the accuracy of its key assumptions; risks related to our corporate restructurings, including our ability to outsource certain operations, realize expected cost savings and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA or AMPYRA to meet market demand; our reliance on third-party manufacturers for the timely production of commercial supplies of INBRIJA and AMPYRA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA or AMPYRA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; our ability to satisfy our obligations to distributors and collaboration partners outside the U.S. relating to commercialization and supply of INBRIJA and AMPYRA; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions because, among other reasons, acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release, except as may be required by law.

###

EX-101.SCH 3 acor-20221220.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 acor-20221220_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 acor-20221220_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g368917g43g72.jpg GRAPHIC begin 644 g368917g43g72.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Dec. 20, 2022
Cover [Abstract]  
Entity Registrant Name ACORDA THERAPEUTICS INC
Amendment Flag false
Entity Central Index Key 0001008848
Document Type 8-K
Document Period End Date Dec. 20, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-31938
Entity Tax Identification Number 13-3831168
Entity Address, Address Line One 2 Blue Hill Plaza
Entity Address, Address Line Two 3rd Floor
Entity Address, City or Town Pearl River
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10965
City Area Code (914)
Local Phone Number 347-4300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ACOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d368917d8k_htm.xml IDEA: XBRL DOCUMENT 0001008848 2022-12-20 2022-12-20 ACORDA THERAPEUTICS INC false 0001008848 8-K 2022-12-20 DE 001-31938 13-3831168 2 Blue Hill Plaza 3rd Floor Pearl River NY 10965 (914) 347-4300 false false false false Common Stock, $0.001 par value per share ACOR NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d368917d8k.htm 7 d368917d8k.htm acor-20221220.xsd acor-20221220_lab.xml acor-20221220_pre.xml d368917dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d368917d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d368917d8k.htm" ] }, "labelLink": { "local": [ "acor-20221220_lab.xml" ] }, "presentationLink": { "local": [ "acor-20221220_pre.xml" ] }, "schema": { "local": [ "acor-20221220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acor", "nsuri": "http://www.acorda.com/20221220", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d368917d8k.htm", "contextRef": "duration_2022-12-20_to_2022-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d368917d8k.htm", "contextRef": "duration_2022-12-20_to_2022-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acorda.com//20221220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-22-309544-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-309544-xbrl.zip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end